Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hangzhou Chance Pharmaceuticals

Request full access

A clinical-stage biotechnology company focusing on discovering

Hangzhou, ChinaFounded 2015Biotech & Life Sciences

About Hangzhou Chance Pharmaceuticals

Hangzhou Chance Pharmaceuticals is a clinical-stage biotechnology firm established in 2015, specializing in the development and commercialization of inhalation therapies. The company was co-founded by Donghao Chen, who serves as CEO, along with Lan Chen, Peng Huang, and Guobao Zhao. Dr. Donghao Chen's background is deeply rooted in inhalation technology; he conducted post-doctoral training at M.I.T. in the lab that invented the ARCUS inhalation technology and later worked at Advanced Inhalation Research (AIR) and Alkermes as the CMC lead for an inhaled insulin therapy. This specialized experience provides a strong scientific foundation for the company's focus.

The company's business model centers on developing a pipeline of therapies for debilitating conditions such as chronic obstructive pulmonary disease (COPD), asthma, and central nervous system disorders. Revenue generation is anticipated through strategic partnerships, distribution agreements, and the eventual commercialization of its drug candidates. A key agreement was established with Acorda Therapeutics in May 2023 to distribute and supply INBRIJA®, a treatment for OFF episodes in Parkinson's disease patients, in Greater China. Under this agreement, Chance Pharmaceuticals will pay Acorda an upfront fee, along with milestone payments and a fixed fee per unit supplied.

Chance Pharmaceuticals leverages two core technology platforms for creating dry powder inhalation (DPI) therapies: a traditional milling and mixing platform and a proprietary spray-drying platform. The spray-drying technology is particularly notable as it allows for the formulation of biological macromolecules and low-activity drugs into highly efficient inhalation powders for deep lung or systemic delivery. The company's pipeline includes candidates like CXG87, an enhanced formulation of budesonide/formoterol inhalation powder currently advancing to Phase III clinical trials, and CXF11, a tiotropium bromide inhalation drug for preventing bronchospasm in COPD patients. To support its development and commercialization goals, the company is building manufacturing facilities compliant with FDA and EMA quality standards.

The company has successfully secured significant funding to advance its pipeline. It raised $30 million in a Series C round in October 2021, followed by a Series C+ round in January 2022. Most recently, in March 2025, Chance Pharma completed another funding round with participation from investors Heda Health Fund and Qihang Venture Capital to accelerate its Phase III trials and develop new formulations.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
58.2/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
SaaS
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Mar 2025 $0 — Undisclosed ↗
SERIES COther financing Oct 2021 $30M $120M Shenzhen Guozhong Venture Capital Management · CMS · HEDA Ventures · Lapam Capital —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Hangzhou Chance Pharmaceuticals website traffic

Latest recorded traffic for Hangzhou Chance Pharmaceuticals is 290 monthly website visits, down 79.3% over the last three months. Hangzhou Chance Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits290 3-month web change-79.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hangzhou Chance Pharmaceuticals in the Hangzhou ecosystem

Live from Dealroom

The Hangzhou Chance Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Delian Capital

Series A3 investors entered at this stage

  • Shenzhen Guozhong Venture Capital Management
  • Kaitai Capital
  • Yipinhong Pharmaceutical

Series B and later3 investors entered at this stage

  • Lapam Capital
  • CMS
  • HEDA Ventures

Other known investors1 additional known investor

  • Massachusetts Institute of Technology
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hangzhou Chance Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hangzhou Chance Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.